LitAlert ~~ GeneLit.com

    • Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers.
    • Li A, Hao S, Luo J, Zi Y, Lan Z, Zhou T, Zhi Q, Zhan J, Sun G, Shi Y, Luo D.
    • J Oncol. 2022 Mar 26;2022:9390539. doi: 10.1155/2022/9390539.
    • Cancer Risk Variants Found in Significant Subset of Sarcoma Patient Germlines.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Mar 25.
    • Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    • Phillips KA, Friedlander ML.
    • J Clin Oncol. 2022 Mar 25:JCO2200325. doi: 10.1200/JCO.22.00325. Epub ahead of print.

    Meta-Analysis:

    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.

    • Health influenced by genetics: A first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population.
    • Boujemaa M, Mighri N, Chouchane L, Boubaker MS, Abdelhak S, Boussen H, Hamdi Y.
    • PLoS One. 2022 Mar 25;17(3):e0265638. doi: 10.1371/journal.pone.0265638.
    • Intra-tumoral CD8+ T-cell infiltration and PD-L1 positivity in homologous recombination deficient pancreatic ductal adenocarcinoma.
    • Zogopoulos G, Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant R, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, Foulkes WD, Gallinger S, Guiot MC, Gao Z.
    • Front Oncol. 2022 Mar 23;12:860767. doi: 10.3389/fonc.2022.860767.
    • Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.
    • Clarfield L, Diamond L, Jacobson M.
    • Curr Oncol. 2022 Mar 21;29(3):2132-2140. doi: 10.3390/curroncol29030172.
    • The Breast Cancer Screening and Timing of Breast MRI-Experience in a Genetic High-Risk Screening Clinic in a Comprehensive Cancer Center.
    • Wang X, Chang MD, Lee MC, Niell BL.
    • Curr Oncol. 2022 Mar 19;29(3):2119-2131. doi: 10.3390/curroncol29030171.
    • Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
    • Catalano F, Borea R, Puglisi S, Boutros A, Gandini A, Cremante M, Martelli V, Sciallero S, Puccini A.
    • Cancers (Basel). 2022 Mar 9;14(6):1388. doi: 10.3390/cancers14061388.
    • Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer.
    • Plata Bello A, Tamayo Jover MA, Gutierrez Nicolas F, Acosta López S, Concepción Masip T, Plata Bello J.
    • Arch Esp Urol. 2022 Mar;75(2):195-202. English, Spanish.
    • Review